What are the recommended next systemic therapy options for a patient with HER2‑positive metastatic breast cancer who has progressed after receiving trastuzumab‑deruxtecan (Enhertu)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Post-Enhertu Treatment Options for HER2-Positive Metastatic Breast Cancer

After progression on trastuzumab deruxtecan (Enhertu), continue with sequential HER2-targeted therapy, specifically trastuzumab emtansine (T-DM1) or tucatinib-based combinations, as these demonstrate clinical benefit and are feasible in the post-T-DXd setting.

Treatment Algorithm After Enhertu Progression

Primary Recommendation: Continue HER2-Targeted Therapy

The ASCO guidelines explicitly state that if HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy, clinicians should recommend second-line HER2-targeted therapy-based treatment 1. While these guidelines position T-DXd as the preferred second-line agent, the principle of continuing HER2-directed therapy remains valid after T-DXd failure.

Specific Treatment Options

Third-Line Setting (Post-T-DXd):

  • Tucatinib + Capecitabine + Trastuzumab: This is the preferred strategy in the third-line setting, particularly for patients with or without CNS metastases, given demonstrated survival benefits 2

  • Trastuzumab Emtansine (T-DM1): If not previously used, T-DM1 remains an option 3

Fourth-Line and Beyond:

  • Margetuximab + chemotherapy
  • Neratinib + capecitabine
  • Trastuzumab + chemotherapy 2

Real-World Evidence Supporting Sequential HER2 Therapy

The EN-SEMBLE study provides critical real-world data on post-T-DXd treatment 4. In 664 patients who received treatment after T-DXd:

  • 486/664 patients (73%) received another anti-HER2 therapy as first post-T-DXd treatment
  • 361/664 patients received anti-HER2 antibodies
  • 113/664 patients received HER2-tyrosine kinase inhibitors (TKIs)
  • Median progression-free survival was 4.1 months (95% CI 3.9-4.5)
  • Median overall survival was 16.2 months (95% CI 13.8-17.2)

Key finding: Outcomes were similar between anti-HER2 antibodies and HER2-TKIs, indicating both are viable options 4.

Special Considerations

Patients Who Discontinued T-DXd Due to Adverse Events

Real-world data shows that patients who discontinued T-DXd due to adverse events (including ILD) had numerically longer progression-free survival and overall survival with subsequent therapy 4. This suggests these patients may derive particular benefit from continued HER2-targeted treatment.

Patients Who Responded to T-DXd

Those who achieved complete or partial response to T-DXd also demonstrated numerically longer outcomes with subsequent therapy 4, supporting the continuation of HER2-targeted approaches.

Interstitial Lung Disease (ILD) Concerns

Critical safety data: The ILD recurrence/exacerbation rate was only 3.2% during first post-T-DXd treatment 4. This low rate indicates that patients who developed ILD during T-DXd can safely receive subsequent therapies, including other HER2-targeted agents.

HER2 Status Re-evaluation

Important caveat: HER2 loss occurs in 32.4% of patients following T-DXd treatment, with an additional 29.4% showing decreased HER2 expression 5. Re-biopsy and HER2 reassessment should be strongly considered before initiating alternate HER2-targeted therapies that require HER2 overexpression for efficacy 5.

The FDA label for Enhertu specifically recommends reassessing HER2 status if feasible after prior trastuzumab-based therapy 6.

Hormone Receptor-Positive Disease

For patients with HR-positive/HER2-positive disease, the ASCO guidelines allow flexibility 1:

  • HER2-targeted therapy plus chemotherapy (preferred)
  • Endocrine therapy plus trastuzumab or lapatinib (selected cases)
  • Endocrine therapy alone (highly selected cases with low disease burden or contraindications)

When chemotherapy ends, add endocrine therapy to the HER2-targeted therapy when the cancer progresses 1.

CNS Metastases

If CNS involvement is present, tucatinib + capecitabine + trastuzumab should be prioritized over other options given its demonstrated CNS activity 2.

Common Pitfalls to Avoid

  1. Don't abandon HER2-targeted therapy: The evidence strongly supports sequential HER2-directed treatment even after T-DXd progression 4

  2. Don't assume ILD precludes further treatment: The recurrence rate is low (3.2%), and many patients can safely continue with other regimens 4

  3. Don't skip HER2 re-testing: Nearly one-third of patients lose HER2 expression post-T-DXd, which may impact treatment selection 5

  4. Don't use chemotherapy alone: Unless HER2 status has been lost, continue HER2-targeted agents with chemotherapy 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.